Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81
Document › Details

Merck KGaA. (31/3/20). "Press Release: Merck Successfully Divests Allergopharma". Darmstadt.

Region Region Europe
Organisations Organisation Merck KGaA
  Group Merck (DE) (Group)
  Organisation 2 Allergopharma GmbH & Co. KG
  Group Dermapharm (Group)
Products Product antiallergic
Index term Index term Merck (DE)–Dermapharm: investment, 202002–202003 acquisition €na of Merck’s allergy business Allergopharma by Dermapharm Holding SE
Person Person Segeberg, Friederike (Merck (DE) 202002 Head Media Relations)

Merck, a leading science and technology company, today completed the divestment of Allergopharma to Dermapharm Holding SE (“Dermapharm”) following regulatory approval and the satisfaction of other customary closing conditions. With the successful transaction closing, the Healthcare business sector will further sharpen its focus on the development of innovative medicines for difficult-to-treat diseases.

The allergy business of Merck in Europe was transferred to Dermapharm on March 31. The transfer of the Allergopharma business in China is planned for the second half of 2020. The two parties have agreed not to disclose the purchase price.

For more information, please contact
Friederike Segeberg
+49 6151 72-6328

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to to register online, change your selection or discontinue this service.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of € 16.2 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Record changed: 2020-04-22


Picture [iito] No Tracking 650x80px

More documents for Merck (DE) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

» top